Objective: To determine the efficacy of statin therapy in AF prevention in women.
Design: Cohort study using data obtained in the Heart and Estrogen-Progestin Replacement Study (HERS).
Setting: Secondary analysis of a multicenter randomized, controlled clinical trial.
Patients: 2673 post-menopausal women with coronary disease.
Main outcome measures: AF prevalence at baseline and incident AF over a mean follow-up of 4.1 years.
Results: We identified 88 women with AF: 29 at baseline and 59 during follow-up. Women with AF were significantly less likely to be taking a statin at study enrollment than those without AF (22% vs. 37%, p = 0.003). Baseline statin use was associated with a 65% lower odds of having AF at baseline after controlling for age, race, history of myocardial infarction or revascularization, and history of heart failure (odds ratio 0.35, 95% confidence interval [CI] 0.13 - 0.93, p = 0.04). The risk of developing AF during the study among those free of AF at baseline, adjusted for the same covariates, was 55% less for those on statin therapy (hazard ratio 0.45, 95% CI 0.26-0.78, p = 0.004).
Conclusions: Statin therapy is associated with a lower prevalence and incidence of AF after adjustment for potential confounders in post-menopausal women with coronary disease.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.